- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07475845
Teenthrive 2 : Traitements pour améliorer l'humeur chez les adolescents
Teenthrive 2 : Traitements pour améliorer l'humeur des adolescents
In this study, we will conduct a pilot RCT of a yoga-based intervention (YBI) vs. group cognitive-behavioral therapy (gCBT) at two sites. We will recruit 48 adolescent participants each in Columbus, OH and Boston, MA (96 total). We have a priori targets for indices of feasibility and acceptability, including recruitment rate, retention for assessments, class attendance, interventionist fidelity to manuals, and participant satisfaction. We hypothesize that we will meet these metrics at both sites.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
In this study, we will conduct a pilot RCT of a yoga-based intervention (YBI) vs. group cognitive-behavioral therapy (gCBT) at two sites. We will recruit 48 adolescent participants each in Columbus, OH and Boston, MA (96 total). We have a priori targets for indices of feasibility and acceptability, including recruitment rate, retention for assessments, class attendance, interventionist fidelity to manuals, and participant satisfaction. We hypothesize that we will meet these metrics at both sites. We will examine preliminary outcomes of depression, functional impairment, and anxiety, as well as engagement of hypothesized mechanisms of self-compassion, and metacognitive awareness. Participants will be adolescents with depression who will receive their assigned intervention for 3 months and be followed for 3 additional months. Parents will also be invited to participate in assessments regarding their child. Adolescent participants will be comprised of Set A (n=72) vs. Set B (where Set B participants do not meet Set A criteria for severity of depression symptoms or stability of other depression treatment. For both sets, in-person CBT groups and the yoga intervention will occur on the campus of the study hospital site. Randomization will be stratified by site and by set (A/B). Masked evaluators will assess depression symptom severity, which will be the primary outcome in a future fully-powered effectiveness trial.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Bailey O'Keeffe, MA
- Numéro de téléphone: 401-455-6219
- E-mail: bokeeffe@butler.org
Sauvegarde des contacts de l'étude
- Nom: Julie Desaulniers
- Numéro de téléphone: 401-455-6219
- E-mail: jdesaulniers@butler.org
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Beth Israel Deaconess Medical Center
-
Contact:
- Shirley Yen, PhD
- Numéro de téléphone: 617-626-9370
- E-mail: syen1@bidmc.harvard.edu
-
Chercheur principal:
- Shirley Yen, PhD
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43215
- Recrutement
- Nationwide Children's Hospital
-
Chercheur principal:
- Jennifer Hughes, PhD
-
Contact:
- Jenny Hughes, PhD
- Numéro de téléphone: 614-722-6811
- E-mail: Jennifer.Hughes@nationwidechildrens.org
-
Contact:
- John Psurney
- Numéro de téléphone: 614-355-4132
- E-mail: John.Psurny@nationwidechildrens.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Set A Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 10 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia;
- Be aged 12-18;
- Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider);
- Be able to read and write in English;
- Provide consent/assent appropriate to age;
- Be able to attend group session times:
- Have access to a private space once per week that is suitable for synchronous intervention sessions.
Set A Exclusion criteria: Adolescents will be excluded if they:
- Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia;
- Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation;
- Have severe depression (QIDS-A-CR score > = 16);
- Have moderate or high risk for suicide (Response of "yes" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months).
- Have suicide ideation (Response of "yes" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy)
- Are pregnant;
- Are currently (past 4 weeks) engaged in yoga classes or in gCBT;
- Have had substantive changes in other psychiatric treatment in the previous 4 weeks (e.g., started a new depression medication; stopped or started attending psychotherapy).
- Have a sibling or other household member active in a study intervention (for this study) at the same time.
Set B Eligibility criteria
Participants who are not eligible for Set A may be enrolled in Phase 2 Set B, such that they will be eligible to attend classes but their data will not be considered in our main analyses.
Set B Inclusion Criteria. In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Have elevated depressive symptoms, defined by: a) a score of 1 or greater on the PHQ-2 and 5 or greater on the PHQ-8 at screening; and b) a score of 6 or higher on the Quick Inventory of Depression-Adolescent Version-Clinician Rating (QIDS-A-CR), including either sad mood or anhedonia;
- Be aged 12-18;
- Be allowed to participate in gym class or sports at school (or, if not, medically cleared by their primary care provider or other relevant healthcare provider);
- Be able to read and write in English;
- Provide consent/assent appropriate to age;
- Be able to attend group session times:
- Have access to a private space once per week that is suitable for synchronous intervention sessions.
Set B Exclusion criteria: Adolescents will be excluded if they:
- Meet criteria for lifetime bipolar I disorder, a current psychotic disorder, or current anorexia or bulimia; or currently be in treatment for anorexia or bulimia;
- Meet criteria for substance use disorder (SUD) in the previous 12 months, with current symptoms of sufficient severity to interfere with study participation;
- Have severe depression (QIDS-A-CR score > = 16);
- Have moderate or high risk for suicide (Response of "yes" on CSSRS-Screener item 3,4,5,6 with regard to the past 3 months).
- Have suicide ideation (Response of "yes" on CSSRS- Screener item 2) and do not currently have other mental health treatment (pharmacotherapy or psychotherapy)
- Are pregnant;
- Are currently (past 4 weeks) engaged in yoga classes or in gCBT;
- Have a sibling or other household member active in a study intervention (for this study) at the same time.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Yoga arm
Yoga-based intervention |
This intervention consists of twice-weekly yoga classes. Classes will be led by trained yoga teachers. Each week for 12 weeks, classes will occur once in person (55 mins) and once virtually (30 mins). |
|
Comparateur actif: gCBT arm
group CBT |
This intervention consists of twice-weekly group CBT sessions. Sessions will be led by trained behavioral health specialists. Each week for 12 weeks, sessions will occur once in person (55 mins) and once virtually (30 mins). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Credibility
Délai: Start of treatment
|
Assessed by Credibility scale of Credibility Expectancy Questionnaire |
Start of treatment
|
|
Expectancy
Délai: Start of treatment
|
Assessed by Expectancy scale of Credibility Expectancy Questionnaire |
Start of treatment
|
|
Program Satisfaction
Délai: 12 weeks
|
Assessed by the Client Satisfaction Questionnaire (CSQ-8) |
12 weeks
|
|
Class Attendance
Délai: Week 0-12
|
Assessed via staff observation |
Week 0-12
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Lisa Uebelacker, PhD, Butler Hospital
- Chercheur principal: Shirley Yen, PhD, Beth Israel Deaconess Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2312-001
- R01AT012238 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified data reflecting demographics, primary, and secondary outcomes.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .